New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 23, 2014
09:15 EDTPFEPfizer says tofacitinib met two primary efficacy endpoints in Phase 3 study
Pfizer announced detailed results from the Oral treatment Psoriasis Trial Retreatment study, a Phase 3 study investigating tofacitinib for the treatment of adult patients with moderate-to-severe chronic plaque psoriasis. This three-period study showed that tofacitinib, as a 5 mg or 10 mg pill taken twice daily, met its two primary efficacy endpoints. The safety profile of tofacitinib in OPT Retreatment was consistent with previous studies and there were no new safety findings in this trial. The first primary endpoint of OPT Retreatment evaluated the maintenance of clinical response in patients who remained on tofacitinib after an initial treatment phase compared to patients who were switched to placebo. The second primary endpoint examined patients who lost half of their original clinical response during the withdrawal phase, and measured the proportion of these patients who regained their original clinical response after restarting treatment with tofacitinib. Throughout the study, the efficacy response was measured by the proportion of subjects achieving a Physician’s Global Assessment response of “clear” or “almost clear” skin and the proportion of subjects achieving at least a 75% reduction in the Psoriasis Area and Severity Index, two commonly used measures of efficacy in psoriasis.
News For PFE From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 30, 2015
07:35 EDTPFEPfizer issues to Repligen a notice of termination under 2012 license agreement
Subscribe for More Information
06:34 EDTPFEObama to propose $215M for major medical program, CNBC says
Subscribe for More Information
06:30 EDTPFEEli Lilly FY15 EPS guidance does not include 12c potential charge
Subscribe for More Information
January 29, 2015
08:15 EDTPFEOPKO Health, Pfizer receive regulatory clearance for global agreement
Subscribe for More Information
January 28, 2015
07:39 EDTPFEPfizer CEO says company not in need of big M&A deal, FT reports
Subscribe for More Information
January 27, 2015
07:16 EDTPFEPfizer drops 2.7% after FY15 outlook miss expectations
Subscribe for More Information
07:07 EDTPFEPfizer sees FY15 adjusted EPS $2.00-$2.10, consensus $2.18
Subscribe for More Information
07:01 EDTPFEPfizer reports Q4 adjusted EPS 54c, consensus 53c
Reports Q4 revenue $13.1B, consensus $12.9B.
January 26, 2015
16:15 EDTPFEPfizer commits to lower price for Prevenar 13 in developing countries
Subscribe for More Information
15:40 EDTPFENotable companies reporting before tomorrow's open
Subscribe for More Information
13:29 EDTPFEEarnings Preview: Pfizer set to report Q4 results as generics impact Celebrex
Subscribe for More Information
January 23, 2015
16:08 EDTPFETeva volatility elevated, Pfizer approached late last year, Bloomberg says
Teva (TEVA) overall option implied volatility of 25 compares to its 26-week average of 23 according to Track Data, suggesting large price movement into Pfizer (PFE) approach late last year, Bloomberg says.
16:04 EDTPFETeva rebuffed Pfizer approach late last year, Bloomberg says
Subscribe for More Information
January 22, 2015
11:23 EDTPFEPfizer says CHMP adopted positive opinion on Prevenar 13 expansion
Subscribe for More Information
January 21, 2015
12:30 EDTPFEGlaxoSmithKline 'admired' by Pfizer CEO, FT reports
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use